TempraMed Technologies (FRA:9DY) Research & Development: €0.36 Mil (TTM As of Mar. 2026)


FRA:9DY TempraMed Technologies Ltd FRA:9DY
10 GF Score
Price €0.33
! 5 Warning Signs
View Full Analysis

What is TempraMed Technologies Research & Development?

TempraMed Technologies FRA:9DY -18.63% 10 Research & Development is €0.36 Mil as of Mar. 2026. GuruFocus rates FRA:9DY with a GF Score™ of 10/100. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. TempraMed Technologies's Research & Development for the three months ended in Mar. 2026 was €0.11 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €0.36 Mil.

TempraMed Technologies  (FRA:9DY) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

TempraMed Technologies Research & Development Related Terms

TempraMed Technologies Research & Development Historical Data

* Premium members only.

The historical data trend for TempraMed Technologies's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TempraMed Technologies Research & Development Chart

TempraMed Technologies Annual Data
Trend Dec23 Dec24 Dec25
Research & Development
0.00 0.13 0.25

TempraMed Technologies Quarterly Data
Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only 0.01 0.04 0.08 0.12 0.11
FRA:9DY
10GF Score
TempraMed Technologies Ltd FRA:9DY
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TempraMed Technologies Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.36 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.36 Mil mean?
TempraMed Technologies (FRA:9DY) has a Research & Development of €0.36 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on TempraMed Technologies and its competitors.
Is TempraMed Technologies' Research & Development too high?
TempraMed Technologies' current Research & Development is €0.36 Mil. Overall, TempraMed Technologies has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does TempraMed Technologies' Research & Development compare to ABT and SYK?
TempraMed Technologies' Research & Development of €0.36 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on TempraMed Technologies and its competitors. TempraMed Technologies's current Research & Development is €0.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TempraMed Technologies stock overvalued right now?
TempraMed Technologies (FRA:9DY) has a current Research & Development of €0.36 Mil. The current Research & Development is €0.36 Mil. TempraMed Technologies' overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For TempraMed Technologies (FRA:9DY), the current Research & Development is €0.36 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TempraMed Technologies Business Description

Other Exchanges VIVI:Canada
Address Heh B’Iyar 14, Tel-Aviv, ISR, 6209307
TempraMed Technologies Ltd through its subsidiary, engaged in developing patent-protected technology designed to serve a broad range of medical and consumer products. TempraMed's primary focus is revolutionizing storage and management of injectable for temperature-sensitive medications. This inventive technology ensures adequate temperature storage conditions to medications without requiring power source or human intervention for years.
10GF Score

Get the complete analysis for FRA:9DY

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.33
Price